https://www.selleckchem.com/products/blu-667.html
80 [95% CI 0.60, 1.07]). However, this association became statistically significant after excluding RCTs comparing metformin with sulfonylureas, SGLT-2 inhibitors or GLP-1 analogues (MH-OR 0.71 [0.51, 0.99]). Metformin was associated with a lower risk of MACEs compared with comparator treatments (n=2 RCTs; MH-OR 0.52 [0.37, 0.73]), p0.001. Similar results were obtained in a post-hoc analysis including all RCTs fulfilling criteria for inclusion in the analysis (MH-OR 0.57 [0.42, 0.76]). This updated meta-analysis suggests that metfom
Like
Comment
Share
